T Cell Epitope Hierarchy in Experimental Autoimmune Models

Immunogenomics and Human Disease

Volumn , Issue , 2006, Pages 327-349

  Buzas, Edit ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Alternative splicing; Autoimmune inflammation; Destructive processing; Dual TCR expression; Endogenous self priming; Immunodominance; Intramolecular epitope spreading; Superagonist ligands; Supercryptic epitopes

Indexed keywords

EID: 70350017704     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470034092.ch14     Document Type: Chapter

References (97)

1. Anderson AC, Waldner H, Turchin V, Jabs C, Prabhu Das M, Kuchroo VK, Nicholson LB. 2000a. Autoantigen-responsive T cell clones demonstrate unfocused TCR cross-reactivity toward multiple related ligands: implications for autoimmunity. Cell Immunol 202(2): 88-96.
2. Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, Kuchroo VK. 2000b. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J Exp Med 191(5): 761-770.
3. Andersson EC, Hansen BE, Jacobsen H, Madsen LS, Andersen CB, Engberg J, Rothbard JB, McDevitt GS, Malmstrom V, Holmdahl R, Svejgaard A, Fugger L. 1998. Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci USA 95(13): 7574-7579.
4. Anderton SM. 2004. Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol 16(6): 753-758.
5. Anderton SM, Wraith DC. 2002a. Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol 2(7): 487-498.
6. Anderton SM, Viner NJ, Matharu P, Lowrey PA, Wraith DC. 2000. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat Immunol 3(2): 175-181.
7. Backlund J, Treschow A, Bockermann R, Holm B, Holm L, Issazadeh-Navikas S, Kihlberg J, Holmdahl R. 2002a. Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen-induced arthritis. Eur J Immunol 32(12): 3776-3784.
8. Backlund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J, Burkhardt H, Holmdahl R. 2002b. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 99(15): 9960-9965.
9. Bankovich AJ, Girvin AT, Moesta AK, Garcia KC. 2004. Peptide register shifting within the MHC groove: theory becomes reality. Mol Immunol 40(14-15): 1033-1039.
10. Bhardwaj V, Kumar V, Geysen HM, Sercarz EE. 1993. Degenerate recognition of a dissimilar antigenic peptide by myelin basic protein-reactive T cells. Implications for thymic education and autoimmunity. J Immunol 151(9): 5000-5010.
11. Bhardwaj V, Kumar V, Grewal IS, Dao T, Lehmann PV, Geysen HM, Sercarz EE. 1994. T cell determinant structure of myelin basic protein in B10.PL, SJL/J, and their F1S. J Immunol 152(8): 3711-3719.
12. Bhayani H, Paterson Y. 1989. Analysis of peptide binding patterns in different major histocompatibility complex/T cell receptor complexes using pigeon cytochrome c-specific T cell hybridomas. Evidence that a single peptide binds major histocompatibility complex in different conformations. J Exp Med 170(5): 1609-1625.
13. Burchell J, Taylor-Papadimitriou J, Boshell M, Gendler S, Duhig T. 1989. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 44(4): 691-696.
14. Buzás EI, Mikecz K, Glant TT. 1996. Aggrecan: a target molecule of autoimmune reactions. Pathol Oncol Res 2(4): 219-228.
15. Buzás EI, Brennan FR, Mikecz K, Garzo M, Negroiu G, Hollo K, Cs-Szabo G, Pintye E, Glant TT. 1995. A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice. J Immunol 155(5): 2679-2687.
16. Buzás EI, Mikecz K, Finnegan A, Hudecz F, Glant TT. 1999. T-cell recognition of differentially tolerated epitopes of human cartilage proteoglycan (aggrecan) in arthritis. Arthrit Rheum 42(suppl 9): S259.
17. Buzás EI, Hanyecz A, Murad Y, Hudecz F, Rajnavolgyi E, Mikecz K, Glant TT. 2003. Differential recognition of altered peptide ligands distinguishes two functionally discordant (arthritogenic and nonarthritogenic) autoreactive T cell hybridoma clones. J Immunol 171(6): 3025-3033.
18. Buzás EI, Végvári A, Murad YM, Finnegan A, Mikecz K, Glant TT. 2005. T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis. Cell Immunol (in press).
19. Cao L, Goodin R, Wood D, Moscarello MA, Whitaker JN. 1999. Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. Biochemistry 38(19): 6157-6163.
20. Chou YK, Vandenbark AA, Jones RE, Hashim G, Offner H. 1989. Selection of encephalitogenic rat T-lymphocyte clones recognizing an immunodominant epitope on myelin basic protein. J Neurosci Res 22(2): 181-187.
21. Corthay A, Nandakumar KS, Holmdahl R. 2001. Evaluation of the percentage of peripheral T cells with two different T cell receptor alpha-chains and of their potential role in autoimmunity. J Autoimmun 16(4): 423-429.
22. Corthay A, Backlund J, Broddefalk J, Michaelsson E, Goldschmidt TJ, Kihlberg J, Holmdahl R. 1998. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 28(8): 2580-2590.
23. Dailey DC, Alderete JF. 1991. The phenotypically variable surface protein of Trichomonas vaginalis has a single, tandemly repeated immunodominant epitope. Infect Immun 59(6): 2083-2088.
24. De Groot AS, Rappuoli R. 2004. Genome-derived vaccines. Expert Rev Vaccines 3(1): 59-76.
25. Diegel ML, Chen F, Laus R, Graddis TJ, Vidovic D. 2003. Major histocompatibility complex class Irestricted presentation of protein antigens without prior intracellular processing. Scand J Immunol 58(1): 1-8.
26. Domenech N, Henderson RA, Finn OJ. 1995. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155(10): 4766-4774.
27. Doyle HA, Mamula MJ. 2001. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 22(8): 443-449.
28. Doyle HA, Mamula MJ. 2002. PostTranslational protein modifications: new flavors in the menu of autoantigens. Curr Opin Rheumatol 14(3): 244-249.
29. Eberl G, Renggli J, Men Y, Roggero MA, Lopez JA, Corradin G. 1999. Extracellular processing and presentation of a 69-mer synthetic polypeptide to MHC class I-restricted T cells. Mol Immunol 36(2): 103-112.
30. Esen A. 1990. An immunodominant site of gamma-zein1 is in the region of tandem hexapeptide repeats. J Protein Chem 9(4): 453-460.
31. Flower DR. 2003. Towards in silico prediction of immunogenic epitopes. Trends Immunol 24(12): 667-674.
32. Fressinaud C, Sarlieve LL, Vincendon G. 1990. Multiple sclerosis: review of main experimental data and pathogenic hypotheses. Rev Med Interne 11(3): 201-208.
33. Fugger L, Rothbard JB, Sonderstrup-McDevitt G. 1996. Specificity of an HLA-DRB1*0401-restricted T cell response to type II collagen. Eur J Immunol 26(4): 928-933.
34. Glant TT, Mikecz K. 2004. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Meth Mol Med 102: 313-338.
35. Glant TT, Mikecz K, Arzoumanian A, Poole AR. 1987. Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. Arthrit Rheum 30(2): 201-212.
36. Glant TT, Finnegan A, Mikecz K. 2003. Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics. Crit Rev Immunol 23(3): 199-250.
37. Glant TT, Buzas EI, Finnegan A, Negroiu G, Cs-Szabo G, Mikecz K. 1998a. Critical roles of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen recognition and presentation. J Immunol 160(8): 3812-3819.
38. Glant TT, Cs-Szabo G, Nagase H, Jacobs JJ, Mikecz K. 1998b. Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthrit Rheum 41(6): 1007-1018.
39. Glant TT, Bardos T, Vermes C, Chandrasekaran R, Valdez JC, Otto JM, Gerard D, Velins S, Lovasz G, Zhang J, Mikecz K, Finnegan A. 2001. Variations in susceptibility to proteoglycan-induced arthritis and spondylitis among C3H substrains of mice: evidence of genetically acquired resistance to autoimmune disease. Arthrit Rheum 44(3): 682-692.
40. Goodacre JA, Middleton S, Lynn S, Ross DA, Pearson J. 1993. Human cartilage aggrecan CS1 region contains cryptic T-cell recognition sites. Immunology 78(4): 586-591.
41. Graca L, Chen TC, Le Moine A, Cobbold SP, Howie D, Waldmann H. 2005. Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells. Trends Immunol 26(3): 130-135.
42. Guan P, Doytchinova IA, Zygouri C, Flower DR. 2003. MHCPred: bringing a quantitative dimension to the online prediction of MHC binding. Appl Bioinformat 2(1): 63-66.
43. Guerassimov A, Zhang Y, Banerjee S, Cartman A, Leroux JY, Rosenberg LC, Esdaile J, Fitzcharles MA, Poole AR. 1998. Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate. Arthrit Rheum 41(6): 1019-1025.
44. Hanyecz A, Bardos T, Berlo SE, Buzás E, Nesterovitch AB, Mikecz K, Glant TT. 2003. Induction of arthritis in SCID mice by T cells specific for the 'shared epitope' sequence in the G3 domain of human cartilage proteoglycan. Arthrit Rheum 48(10): 2959-2973.
45. Hanyecz A, Berlo SE, Szanto S, Broeren CP, Mikecz K, Glant TT. 2004. Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype. Arthrit Rheum 50(5): 1665-1676.
46. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. 2003. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritisassociated HLA-DRB1*0401 MHC class II molecule. J Immunol 171(2): 538-541.
47. Hollo K, Glant TT, Garzo M, Finnegan A, Mikecz K, Buzás E. 2000. Complex pattern of Th1 and Th2 activation with a preferential increase of autoreactive Th1 cells in BALB/c mice with proteoglycan (aggrecan)-induced arthritis. Clin Exp Immunol 120(1): 167-173.
48. Honeyman MC, Brusic V, Stone NL, Harrison LC. 1998. Neural network-based prediction of candidate T-cell epitopes. Nat Biotechnol 16(10): 966-969.
49. Kyewski B, Derbinski J. 2004. Self-representation in the thymus: an extended view. Nat Rev Immunol 4(9): 688-698.
50. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358(6382): 155-157.
51. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. 1993. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 14(5): 203-208.
52. Leroux JY, Guerassimov A, Cartman A, Delaunay N, Webber C, Rosenberg LC, Banerjee S, Poole AR. 1996. Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. J Clin Invest 97(3): 621-632.
53. Li Y, Li H, Martin R, Mariuzza RA. 2000. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J Mol Biol 304(2): 177-188.
54. Mamitsuka H. 1998. Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Proteins 33(4): 460-474.
55. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, Mazza G, Wraith DC, Watts C. 2002. Destructive processing by asparagine endopeptidase (AEP) limits presentation of a dominant T cell epitope in MBP. Nat Immunol 3(2): 169-174.
56. Maverakis E, van den Elzen P, Sercarz EE. 2001. Self-reactive T cells and degeneracy of T cell recognition: evolving concepts-from sequence homology to shape mimicry and TCR flexibility. J Autoimmun 16(3): 201-209.
57. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182(1): 75-85.
58. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R. 1994. T cell recognition of carbohydrates on type II collagen. J Exp Med 180(2): 745-749.
59. Mikecz K, Glant TT, Poole AR. 1987. Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthrit Rheum 30(3): 306-318.
60. Miller SD, Vanderlugt CL, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, Bluestone JA. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3(6): 739-745.
61. Moudgil KD, Sercarz EE. 1993. Dominant determinants in hen eggwhite lysozyme correspond to the cryptic determinants within its self-homologue, mouse lysozyme: implications in shaping of the T cell repertoire and autoimmunity. J Exp Med 178(6): 2131-2138.
62. Nakagawa Y, Takeshita T, Berzofsky JA, Takahashi H. 2000. Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes. Immunology 101(1): 76-82.
63. Ng B, Yang F, Huston DP, Yan Y, Yang Y, Xiong Z, Peterson LE, Wang H, Yang XF. 2004. Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol 114(6): 1463-1470.
64. Ortutay Z, Polgar A, Gomor B, Geher P, Lakatos T, Glant TT, Gay RE, Gay S, Pallinger E, Farkas C, Farkas E, Tothfalusi L, Kocsis K, Falus A, Buzás EI. 2003. Synovial fluid exoglycosidases are predictors of rheumatoid arthritis and are effective in cartilage glycosaminoglycan depletion. Arthrit Rheum 48(8): 2163-2172.
65. Parker KC, Bednarek MA, Coligan JE. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152(1): 163-175.
66. Phan UT, Maric M, Cresswell P. 2002. Disulfide reduction in major histocompatibility complex class II-restricted antigen processing by interferon-gamma-inducible lysosomal thiol reductase. Meth Enzymol 348: 43-48.
67. Qiao SW, Bergseng E, Molberg O, Xia J, Fleckenstein B, Khosla C, Sollid LM. 2004. Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol 173(3): 1757-1762.
68. Rammensee HG, Friede T, Stevanoviic S. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41(4): 178-228.
69. Reiser JB, Darnault C, Gregoire C, Mosser T, Mazza G, Kearney A, van der Merwe PA, Fontecilla-Camps JC, Housset D, Malissen B. 2003. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat Immunol 4(3): 241-247.
70. Rosloniec EF, Brand DD, Myers LK, Esaki Y, Whittington KB, Zaller DM, Woods A, Stuart JM, Kang AH. 1998. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol 160(6): 2573-2578.
71. Sakai K, Zamvil SS, Mitchell DJ, Lim M, Rothbard JB, Steinman L. 1998. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol 19(1-2): 21-32.
72. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. 1999a. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci USA 96(26): 15050-15055.
73. Santambrogio L, Sato AK, Carven GJ, Belyanskaya SL, Strominger JL, Stern LJ. 1999b. Extracellular antigen processing and presentation by immature dendritic cells. Proc Natl Acad Sci USA 96(26): 15056-15061.
74. Savoie CJ, Kamikawaji N, Sasazuki T, Kuhara S. 1999. Use of BONSAI decision trees for the identification of potential MHC class I peptide epitope motifs. Pacific Symposium on Biocomputers 182-189.
75. Seidah NG, Chretien M. 1997. Eukaryotic protein processing: endoproteolysis of precursor proteins. Curr Opin Biotechnol 8(5): 602-607.
76. Sercarz EE. 2002. Processing creates the self. Nat Immunol 3(2): 110-112.
77. Sercarz EE, Maverakis E. 2003. MHC-guided processing: binding of large antigen fragments. Nat Rev Immunol 3(8): 621-629.
78. Sercarz EE, Maverakis E. 2004. Recognition and function in a degenerate immune system. Mol Immunol 40(14-15): 1003-1008.
79. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. 1993. Dominance and crypticity of T cell antigenic determinants. A Rev Immunol 11: 729-766.
80. Sette A, FleriW, Peters B, Sathiamurthy M, Bui HH, Wilson S. 2005. A roadmap for the immunomics of category A-C pathogens. Immunity 22(2): 155-161.
81. Singh KK, Zhang X, Patibandla AS, Chien P Jr, Laal S. 2001. Antigens of Mycobacterium tuberculosis expressed during preclinical tuberculosis: serological immunodominance of proteins with repetitive amino acid sequences. Infect Immun 69(6): 4185-4191.
82. Sloan-Lancaster J, Allen PM. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. A Rev Immunol 14: 1-27.
83. Sung MH, Zhao Y, Martin R, Simon R. 2002. T-cell epitope prediction with combinatorial peptide libraries. J Comput Biol 9(3): 527-539.
84. Szanto S, Bardos T, Szabo Z, David CS, Buzás EI, Mikecz K, Glant TT. 2004. Induction of arthritis in HLA-DR4-humanized and HLA-DQ8-humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non-MHC) genetic background. Arthrit Rheum 50(6): 1984-1995.
85. Tsunoda I, Fujinami RS. 1996. Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J Neuropathol Exp Neurol 55(6): 673-686.
86. Umezawa ES, Shikanai-Yasuda MA, da Silveira JF, Cotrim PC, Paranhos G, Katzin AM. 1993. Trypanosoma cruzi: detection of a circulating antigen in urine of chagasic patients sharing common epitopes with an immunodominant repetitive antigen. Exp Parasitol 76(4): 352-357.
87. Vanderlugt CL, Miller SD. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2(2): 85-95.
88. Viner NJ, Nelson CA, Deck B, Unanue ER. 1996. Complexes generated by binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J Immunol 156: 2365-2368.
89. Von Delwig A, Musson JA, McKie N, Gray J, Robinson JH. 2003. Regulation of peptide presentation by major histocompatibility complex class II molecules at the surface of macrophages. Eur J Immunol 33(12): 3359-3366.
90. Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG. 2001. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166(10): 6430-6436.
91. Wildbaum G, Netzer N, Karin N. 2002. Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading. J Clin Invest 110(5): 701-710.
92. Yin L, Yu M, Edling AE, Kawczak JA, Mathisen PM, Nanavati T, Johnson JM, Tuohy VK. 2001. Preemptive targeting of the epitope spreading cascade with genetically modified regulatory T cells during autoimmune demyelinating disease. J Immunol 167(11): 6105-6112.
93. Yu M, Johnson JM, Tuohy VK. 1996. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183(4): 1777-1788.
94. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. 1986. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 324(6094): 258-260.
95. Zhang Y, Guerassimov A, Leroux JY, Cartman A, Webber C, Lalic R, de Miguel E, Rosenberg LC, Poole AR. 1998. Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice. Evidence for T cell involvement and the immunosuppressive influence of keratan sulfate on recognition of t and b cell epitopes. J Clin Invest 101(8): 1678-1686.
96. Zhao Y, Gran B, Pinilla C, Markovic-Plese S, Hemmer B, Tzou A, Whitney LW, Biddison WE, Martin R, Simon R. 2001. Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J Immunol 167(4): 2130-2141.
97. Zhao Y, Pinilla C, Valmori D, Martin R, Simon R. 2003. Application of support vector machines for T-cell epitopes prediction. Bioinformatics 19(15): 1978-1984.